-
Mashup Score: 2Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia - 7 hour(s) ago
Key PointsDasatinib, asciminib, and prednisone can be safely combined for the dual targeting of BCR::ABL1 in Ph+ acute leukemia.Dasatinib and asciminib com
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3
Program: Oral and Poster Abstracts Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I Hematology Disease Topics & Pathways: Research, Clinical trials, Acute Myeloid Malignancies, AML, Adult, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Treatment Considerations, Biological therapies, Young adult , Myeloid Malignancies, Study Population, Human Mark Blaine Geyer, MD 1,2, Susan DeWolf, MD 3 *, Xiaoli Mi, MD 1, Brian C. Shaffer, MD, MS
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
5- #AML #CARTRX #CD371 https://t.co/rM6WKgR4cH https://t.co/SHVZILA8hn
-
-
Mashup Score: 366th ASH Annual Meeting: Late-Breaking Abstracts Session - 2 month(s) ago
John Koreth, MD, MBBS, PhD, DPhil, Dana-Farber Cancer Institute, Harvard Medical School and Rakhi P. Naik, MD, Johns Hopkins Hospital No releva nt conflicts of interest to declare. This highly anticipated session highlights the Joint Program Committees’ selections of the highest-impact abstracts, featuring substantive, novel, and groundbreaking data that were not available by the general abstract submission deadline and would otherwise not be presented at the ASH annual
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
RT @BloodJournal: Symposia: Late-Breaking Abstracts Program: Marquee Sessions 7:30 am - 9 am PST Meeting Hall B https://t.co/5XKzSlLwYq #AS…
-
-
Mashup Score: 0
Program: Oral and Poster Abstracts Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III Hematology Disease Topics & Pathways: Lymphoid Leukemias, Research, Clinical trials, ALL, Lymphomas, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, T Cell lymphoma, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Technology and Procedures, Gene editing Caroline Diorio, MD 1, Paul Shaughnessy, MD 2, Nosha Farhadfar, MD 2 *,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
21- #TALL #CART #CD7 https://t.co/epYQqzarwS https://t.co/4MGOXyrKmK
-
-
Mashup Score: 1Paper: CD7.Pebl-CART for Patients with Relapsed/Refractory (r/r) T-Cell Acute Lymphoblastic Leukemia (T-ALL) - 2 month(s) ago
Program: Oral and Poster Abstracts Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III Hematology Disease Topics & Pathways: Research, Clinical Practice (Health Services and Quality), Clinical Research, Health outcomes research, Real-world evidence, Adverse Events, Emerging technologies, Technology and Procedures Marco Becilli 1 *, Francesca Del Bufalo, MD, PhD 2 *, Pietro Merli, MD 2 *, Daria Pagliara, MD, PhD 2 *, Chiara Rosignoli, MD 2 *, Valentina Bertaina,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
20- #TALL #CART #CD7 https://t.co/ap2EGkYf0d https://t.co/H2TkmC4CGJ
-
-
Mashup Score: 2
Program: Oral and Poster Abstracts Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II Hematology Disease Topics & Pathways: Research, Clinical trials, Lymphoid Leukemias, ALL, Adult, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Young adult , Study Population, Human, Measurable Residual Disease Armin Ghobadi, MD 1, Ibrahim Aldoss, MD 2, Shannon L. Maude, MD 3,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
19- #TALL #CART #CD7 https://t.co/EBYJIDzNrB https://t.co/exb7hi4vao
-
-
Mashup Score: 1
Program: Oral and Poster Abstracts Session: 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster III Hematology Disease Topics & Pathways: Research, Clinical trials, Clinical Research Mengyun Li 1 *, Qingya Cui 1 *, Xuekai Li 1 *, Wei Cui 1 *, Xiaoqian Chen 1 *, Yan Yu 1 *, Juan Chen 1 *, Xin Zhang 1 *, Liqing Kang 2 *, Lei Yu 2 *, Depei Wu, MD, PhD 1 and Xiaowen Tang 1 * 1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
18- #BALL #CARTRX #TandemCAR https://t.co/5Fnmj10AGV https://t.co/Lu4Ix7Gc6X
-
-
Mashup Score: 1
Program: Oral and Poster Abstracts Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I Hematology Disease Topics & Pathways: Research, Clinical trials, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Cell expansion, Treatment Considerations, Biological therapies, Technology and Procedures Sumithira Vasu, MD, MBBS 1, Evandro Bezerra, MD 2, Nathan Denlinger, DO, MS 2, Nicole Szuminski 1 *, Dina Schneider, PhD 3, Pradyot Dash, PhD 4, Louisa
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
17- #BALL #CARTRX #triCAR https://t.co/h072uYYdjt https://t.co/Ir2NXcPu3e
-
-
Mashup Score: 2
Program: Oral and Poster Abstracts Type: Oral Session: 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Risk Stratification and CAR-T Therapies Hematology Disease Topics & Pathways: Research, Clinical trials, Lymphoid Leukemias, ALL, Adult, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Study Population, Human, Measurable Residual Disease Elias Jabbour, MD 1, Jae H.
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
16- #BALL #CARTRX #Obecel https://t.co/yg1oKEdQUo https://t.co/RjxAllqcxQ
-
-
Mashup Score: 2
Program: Oral and Poster Abstracts Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II Hematology Disease Topics & Pathways: Research, Clinical trials, Lymphoid Leukemias, ALL, Adult, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Study Population, Human Jae H. Park, MD 1, Elias Jabbour, MD 2, Paul Shaughnessy, MD 3, Aaron C. Logan, MD, PhD 4, Karamjeet S Sandhu,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
15- #BALL #CARTX #Obecel #Bridging https://t.co/UbPH2GXyyj https://t.co/heOqrHgmsu
-
Great and promising results! Asciminib+ Dasatinib+Prednisone for Ph+ ALL https://t.co/oJDwTnrnR7